重组人血管内皮抑制素联合化疗治疗晚期结直肠癌的临床疗效  

Clinical outcomes of recombinant human endostatin combined with chemotherapy in the treatment of patients with advanced colorectal cancer

作　　者：樊翠珍[1] 戴红[1] 初玉平[1] 

机构地区：[1]首都医科大学附属北京朝阳医院肿瘤科,北京100020

出　　处：《肿瘤》2010年第12期1065-1068,共4页Tumor

摘　　要：目的:观察重组人血管内皮抑制素注射液联合伊立替康加卡培他滨治疗晚期结直肠癌的有效性和安全性。方法:手术或化疗后出现复发或转移的晚期结直肠癌患者29例,给予重组人血管内皮抑制素联合伊立替康加卡培他滨化疗,每3周为1个化疗周期。1个化疗周期后评价不良反应,2个化疗周期后评价近期客观疗效,并随访生存情况。结果:28例患者可评价疗效,其中完全缓解(complete response,CR)2例、部分缓解(partial response,PR)11例、疾病稳定(stable disease,SD)7例、疾病进展(progressive disease,PD)8例,临床有效率为46.4%(13/28),临床受益率为71.4%(20/28)。中位无进展生存时间和中位总生存时间分别为6.2和13.7个月。结论:重组人血管内皮抑制素联合化疗治疗晚期结直肠癌的近期疗效较好,不良反应可以耐受。Objective：To evaluate the efficacy and safety of recombinant human endostatin combined with irinotecan（CPT-11）plus capecitabine（xeloda）in the treatment of patients with advanced colorectal cancer.Methods：Twenty-nine patients with advanced colorectal cancer confirmed by histopathology were administrated with recombinant human endostatin 15 mg everyday for 14 d by vein infusion plus routine chemotherapy（CPT-11＋capecitabine）.Repeat the cycle every three weeks.The response was evaluated every two cycles and the toxicity was observed.Rusults：Twenty-eight patients were evaluated.Complete response was observed in 2 patients,partial response in 11 patients,stable disease in 7 patients and progressive disease in 8 patients.Overall response rate was 46.4%（13/28）,and the clinical benefit rate was 71.4%（20/28）.Median progression-free survival and overall survival were 6.2 months and 13.7 months,respectively.Conclusion：Recombinant human endostatin combined with chemotherapy seems to be efficient and safe for patients with advanced colorectal cancer,and it is well tolerated.

关 键 词：结直肠肿瘤 重组人血管内皮抑制素 药物疗法 临床结果 

分 类 号：R735.34[医药卫生—肿瘤]